Ability Pharmaceuticals

Ability Pharmaceuticals (AbilityPharma) is a clinical-stage biopharmaceutical company headquartered in Cerdanyola del Vallès (Barcelona), Catalonia, Spain, focused on developing first-in-class cancer therapies through autophagy induction. The company's lead compound, ABTL0812 (Ibrilatazar), is currently in a Phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer across the USA, Spain, France, and Israel, and has shown positive results in Phase 2a trials for endometrial and lung cancer. AbilityPharma investigates drugs that selectively induce cytotoxic autophagy in cancer cells, targeting major oncological unmet needs with a novel mechanism of action.